Using Trastuzumab After Stem Cell Transplant in Breast Cancer
Author Information
Author(s): Banna G L, Aversa S M L, Crivellari G, Ghiotto C, Chiarion-Sileni V, Monfardini S
Primary Institution: Division of Medical Oncology, Istituto Oncologico Veneto, Italy
Hypothesis
The use of antitumoral monoclonal antibodies (moAbs) following nonmyeloablative allogeneic stem cell transplantation might enhance the allogeneic ADCC against tumour cell targets.
Conclusion
Trastuzumab treatment after stem cell transplantation showed some positive effects on liver function and disease progression in one patient, suggesting potential benefits of this approach.
Supporting Evidence
- Trastuzumab treatment was associated with increased NK cell activity.
- One patient showed a rapid decrease in liver failure symptoms after starting trastuzumab.
- The other patient experienced partial remission after adding paclitaxel to trastuzumab.
Takeaway
Doctors tried a new treatment for two women with breast cancer after they had a special type of stem cell transplant, and it helped one of them feel better for a while.
Methodology
Two patients with HER2-positive metastatic breast cancer were treated with trastuzumab after nonmyeloablative allogeneic stem cell transplantation.
Limitations
The study involved only two patients, limiting the generalizability of the findings.
Participant Demographics
Patients were aged 40 and 49 years and were heavily pretreated with multiple chemotherapy lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website